Clearmind Medicine (NASDAQ:CMND) Shares Down 0.8%

Clearmind Medicine Inc. (NASDAQ:CMND) traded down 0.8% during mid-day trading on Thursday . The stock traded as low as $1.15 and last traded at $1.17. 45,654 shares were traded during mid-day trading, a decline of 96% from the average session volume of 1,239,950 shares. The stock had previously closed at $1.18.

Clearmind Medicine Price Performance

The stock has a 50-day moving average of $1.27 and a two-hundred day moving average of $2.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.96 and a quick ratio of 1.96.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.90) EPS for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

A hedge fund recently bought a new stake in Clearmind Medicine stock. Warberg Asset Management LLC purchased a new stake in Clearmind Medicine Inc. (NASDAQ:CMND) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 220,000 shares of the company’s stock, valued at approximately $35,000. Warberg Asset Management LLC owned about 3.14% of Clearmind Medicine as of its most recent filing with the Securities & Exchange Commission. 96.05% of the stock is owned by institutional investors and hedge funds.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.